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Human ehrlichiosis (HME) and human
granulocytic ehrlichiosis (HGE), two emerging
infectious diseases transmitted by ticks, are
caused by Ehrlichia chaffeensis and the HGE
agent of the E. phagocytophila genogroup,
respectively. In the United States, HME and
HGE were first described in 1987 and 1994,
respectively (1). Since then, seroepidemologic
studies have shown that these infections are also
present in other parts of the world.
The first cases of HME and HGE were
reported in Europe in 1991 and 1995,
respectively (2,3). Serologic evidence of HGE has
been found in Norway and Sweden (4). In South
America, a case of E. canis infection was reported
in Venezuela (5). One clinical case of HME has
been reported in Mali, Africa (6). A serosurvey
for HME of 756 patients from eight African
countries suggested that the disease is rare in
Africa (7).
We describe the first serologic survey in
Israel for HME and HGE, which documents the
detection of antibodies reactive with HME and
HGE agents.
Materials and Methods
Sera
One thousand serum samples from patients
in Israel with fever of undetermined cause from
1994 to 1997 were received by the Israel National
Reference Laboratory for Rickettsial Diseases. All
specimens were serologically negative for Mediter-
ranean spotted fever, murine typhus, and Q fever.
Serology
The sera were tested retrospectively for
immunoglobulin (Ig) G antibodies to E. chaffeensis
and  E. canis by indirect immunofluorescence
antibody (IFA) (8). Briefly, DH82 cells heavily
infected with the Israeli strain of E. canis (#611)
(8) or the Arkansas strain of E. chaffeensis were
pelleted and resuspended in growth medium.
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We conducted a retrospective serosurvey of 1,000 persons in Israel who had fever
of undetermined cause to look for Ehrlichia chaffeensis antibodies. Four of five cases
with antibodies reactive to E. chaffeensis were diagnosed in the summer, when ticks are
more active. All patients had influenzalike symptoms with high fever. None of the cases
was fatal. Three serum samples were also seroreactive for antibodies to E. canis, and
one was also reactive to the human granulocytic ehrlichiosis (HGE) agent. The titer to
the HGE agent in this patient was higher than the serum titer to E. chaffeensis, and the
Western blot analysis also indicated that the HGE agent was the primary cause of
infection. We present the first serologic evidence that the agents of human monocytic
ehrlichiosis (HME) and HGE are present in Israel. Therefore, human ehrlichiosis should
be included in the differential diagnoses for persons in Israel who have been exposed
to ticks and have influenzalike symptoms.776 776 776 776 776 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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Table. Clinical and serologic data for patients in Israel with antibodies to Ehrlichia chaffeensis and the human
granulocytic ehrlichiosis agent
Patients
Clinical and serologic data     1       2     3     4     5
Date   7/94     7/94   8/95   2/97   7/97
Sex    F      F    M    M    M
Age (years)   77       8     22    12    52
IFA titer (HME)   1:128     1:256 1:1,024  1:256 1:256
IFA titer E. canis   1:80     1:80 1:640 <1:40 <1:40
IFA titer (HGE) <1:64   <1:64 1:2,048a <1:64 <1:64
Body temperature (°C)   40   39.2   40.2    40   38.5
Symptoms:
Vomiting     -     +     -     -
Headache     +    ++
Chills     +     +
Macular rash     +     +     +
Lymphomegaly     +     +
Neck pain     -     +     -     -     -
Duration (days)     7     >5    12    14    14
Tetracycline therapy     +     +     +     -
Total leukocyte count/µlb   3,700     4,000   3,500     4,000   16,700
Total platelet count/µlc 86,000 272,000 95,000 177,000 318,000
aWestern blot analysis of the serum proved positive for HGE.
bNormal range for total leukocyte count 4,000-10,000/µl.
HGE, human granulocytic ehrlichiosis; HME, human monocytic ehrlichiosis; IFA, immunofluorescence assay.
cNormal range for total platelet count 150,000-450,000/µl.
Five microliters of the suspension were placed in
each well of eight-well teflon-coated slides. The
slides were dried at room temperature for
approximately 30 minutes, fixed in acetone for 15
minutes, and then stored at 40°C. Serum
samples were assayed for IgG by preparing and
testing serum dilutions in PBS at their cutoff
points of 1:64 for E. chaffeensis and 1:40 for
E. canis. Positive sera were subsequently
assayed at twofold dilutions. Positive control
sera were provided by the Centers for Disease
Control and Prevention (CDC).
Serum samples were sent to CDC for
confirmation of results of the HME titers and for
testing for HGE.
Western Blot Analysis
One patient (#3)         sample found positive for
HGE was tested by Western blot at Johns
Hopkins University, Baltimore, Maryland.
Results
Of the 1,000 sera tested, five were found
seropositive with HME (Table). During valida-
tion of the sera for HME antibodies, the CDC
laboratory also found that one patient (#3) had
an antibody titer of 1:2,048 to HGE. This sample
was confirmed positive for HGE by Western blot.
None of the patients documented in this
study had traveled overseas before their illness.
All five cases occurred in persons, three male and
two female, who lived on the coastal plain. Two
of the three men lived in agricultural
settlements. The average age of patients was
34.2 years (8 to 77 years). Four of the five
patients were ill during summer.
The disease lasted up to 14 days. None of the
cases was fatal. None of the patients reported
being bitten by a tick. All patients had fever from
38.5°C to 40.2°C. Clinical signs were inconsis-
tent: macular rash was present in only three
patients and lymphomegaly in two. Four
patients were leukopenic, and two were also
thrombocytopenic. No changes in liver enzymes
were detected in any of the patients.
The antibody titers to E. chaffeensis were
1:128 to 1:1,024. Similar results were obtained by
CDC. Three of the five sera were also
seropositive for E. canis antibodies; however,
their titers were lower than those to E. chaffeensis.777 777 777 777 777 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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Conclusions
We retrospectively looked for E. chaffeensis
antibodies in human patients with fever of
undetermined cause. Four cases of HME were
found, as well as a possible case of HGE with
cross-reacting antibodies to HME.
Four of the five cases were diagnosed in
summer, during peak tick activity. Patients’ ages
were 8 to 77 years. Symptoms were nonspecific,
as has been described (1). All patients had
influenzalike symptoms with high fever. Leuko-
penia was seen in four patients and thrombocy-
topenia in two; both these hematologic changes
are typical of HME.
In our study three sera positive for
E. chaffeensis were also seropositive for E. canis,
unlike the African study in which all
E. chaffeensis-positive sera were seronegative to
E. canis in spite of the known strong cross-
reactivity between the strains (7). The reason for
this lack of cross-reactivity is unknown;
however, reactivity in E. chaffeensis patients to
E. canis antigens may develop only after
prolonged exposure to the Ehrlichia, allowing
expression of common antigens to be revealed.
In one seropositive E. chaffeensis case (#3),
the titer to the HGE agent was higher than to
E. chaffeensis and Western blot analysis for HGE
was positive, which indicates that the HGE
agent was the primary cause of infection.
Serologic reactions with E. chaffeensis have been
demonstrated after HGE infection (9). Cross-
reaction between the two species of Erhlichia
has been found in a small proportion of all HGE
patients tested, which suggests that the causative
Ehrlichiae share antigenic determinants.
Several tick species of the genus Ixodes are
found in Israel, including the I. ricinus, which is
the vector of the disease in Europe, and
I. redikorzevi, which often bites humans (10,11).
Rhipicephalus sanguineus, which is abundant in
Israel, is a potential vector of HME agent.
Coinfection by a number of tickborne diseases is
not uncommon, and persons may be infected by
both HME and HGE agents simultaneously.
A recent serosurvey of jackals in Israel tested
against  E.  canis, E. chaffeensis, and
E. phagocytophila genogroup antigens has
shown that some jackals were seroreactive only
to the E. phagocytophila genogroup antigen (12).
The latter group of Ehrlichia consists of E. equi,
E. phagocytophila, and the HGE agent (13). A
close serologic and genetic relationship has been
shown to exist among these three members,
suggesting that they may be strains of a single
species (1). The finding in jackals adds further
evidence of one or more of the E. phagocytophila
genogroup of Ehrlichiae in Israel.
In conclusion, we have presented the first
serologic evidence that the agents of HME and
HGE are present in Israel. Human ehrlichiosis
should therefore be included in the differential
diagnoses for persons in Israel who have been
exposed to ticks and have influenzalike symptoms.
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